---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000027"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:24:32.166858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock provides 2024 pipeline update; Phase 3 SMA trial topline data expected Q4 2024

## Summary
- Cash and equivalents of ~$280M as of Dec 31, 2023; projected to fund operations into H2 2025.
- Enrollment completed for apitegromab pivotal Phase 3 SAPPHIRE in SMA; topline data expected Q4 2024.
- Phase 2 proof-of-concept trial of apitegromab with GLP-1 RA in obesity to start mid-2024.
- SRK-439 IND for obesity planned in 2025; preclinical data at Keystone Symposia in Feb 2024.
- Presenting at J.P. Morgan Healthcare Conference on Jan 9, 2024 at 1:30 p.m. PT.

## SEC filing metadata
- accession: 0001157523-24-000027
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000115752324000027/0001157523-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000115752324000027/a53878319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000027
- JSON: https://secwatch.observer/filing/0001157523-24-000027.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.